BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

655 related articles for article (PubMed ID: 16014412)

  • 21. Status of treatment strategies for Hutchinson-Gilford progeria syndrome with a focus on prelamin: A posttranslational modification.
    Chen X; Yao H; Andrés V; Bergo MO; Kashif M
    Basic Clin Pharmacol Toxicol; 2022 Oct; 131(4):217-223. PubMed ID: 35790078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells.
    Cao K; Graziotto JJ; Blair CD; Mazzulli JR; Erdos MR; Krainc D; Collins FS
    Sci Transl Med; 2011 Jun; 3(89):89ra58. PubMed ID: 21715679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Presence and distribution of progerin in HGPS cells is ameliorated by drugs that impact on the mevalonate and mTOR pathways.
    Clements CS; Bikkul MU; Ofosu W; Eskiw C; Tree D; Makarov E; Kill IR; Bridger JM
    Biogerontology; 2019 Jun; 20(3):337-358. PubMed ID: 31041622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prelamin A, Zmpste24, misshapen cell nuclei, and progeria--new evidence suggesting that protein farnesylation could be important for disease pathogenesis.
    Young SG; Fong LG; Michaelis S
    J Lipid Res; 2005 Dec; 46(12):2531-58. PubMed ID: 16207929
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progerin impairs chromosome maintenance by depleting CENP-F from metaphase kinetochores in Hutchinson-Gilford progeria fibroblasts.
    Eisch V; Lu X; Gabriel D; Djabali K
    Oncotarget; 2016 Apr; 7(17):24700-18. PubMed ID: 27015553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sulforaphane enhances progerin clearance in Hutchinson-Gilford progeria fibroblasts.
    Gabriel D; Roedl D; Gordon LB; Djabali K
    Aging Cell; 2015 Feb; 14(1):78-91. PubMed ID: 25510262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic involvement in Hutchinson-Gilford progeria syndrome: a mini-review.
    Arancio W; Pizzolanti G; Genovese SI; Pitrone M; Giordano C
    Gerontology; 2014; 60(3):197-203. PubMed ID: 24603298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progerin elicits disease phenotypes of progeria in mice whether or not it is farnesylated.
    Yang SH; Andres DA; Spielmann HP; Young SG; Fong LG
    J Clin Invest; 2008 Oct; 118(10):3291-300. PubMed ID: 18769635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. All-trans retinoic acid and rapamycin normalize Hutchinson Gilford progeria fibroblast phenotype.
    Pellegrini C; Columbaro M; Capanni C; D'Apice MR; Cavallo C; Murdocca M; Lattanzi G; Squarzoni S
    Oncotarget; 2015 Oct; 6(30):29914-28. PubMed ID: 26359359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dermal fibroblasts in Hutchinson-Gilford progeria syndrome with the lamin A G608G mutation have dysmorphic nuclei and are hypersensitive to heat stress.
    Paradisi M; McClintock D; Boguslavsky RL; Pedicelli C; Worman HJ; Djabali K
    BMC Cell Biol; 2005 Jun; 6():27. PubMed ID: 15982412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Accumulation of distinct prelamin A variants in human diploid fibroblasts differentially affects cell homeostasis.
    Candelario J; Borrego S; Reddy S; Comai L
    Exp Cell Res; 2011 Feb; 317(3):319-29. PubMed ID: 20974128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nuclear localization signal deletion mutants of lamin A and progerin reveal insights into lamin A processing and emerin targeting.
    Wu D; Flannery AR; Cai H; Ko E; Cao K
    Nucleus; 2014; 5(1):66-74. PubMed ID: 24637396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disruption of lamin B1 and lamin B2 processing and localization by farnesyltransferase inhibitors.
    Adam SA; Butin-Israeli V; Cleland MM; Shimi T; Goldman RD
    Nucleus; 2013; 4(2):142-50. PubMed ID: 23475125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hutchinson-Gilford progeria syndrome through the lens of transcription.
    Prokocimer M; Barkan R; Gruenbaum Y
    Aging Cell; 2013 Aug; 12(4):533-43. PubMed ID: 23496208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation.
    Yang SH; Meta M; Qiao X; Frost D; Bauch J; Coffinier C; Majumdar S; Bergo MO; Young SG; Fong LG
    J Clin Invest; 2006 Aug; 116(8):2115-21. PubMed ID: 16862216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Farnesyltransferase inhibitor treatment restores chromosome territory positions and active chromosome dynamics in Hutchinson-Gilford progeria syndrome cells.
    Mehta IS; Eskiw CH; Arican HD; Kill IR; Bridger JM
    Genome Biol; 2011 Aug; 12(8):R74. PubMed ID: 21838864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prelamin A and lamin A appear to be dispensable in the nuclear lamina.
    Fong LG; Ng JK; Lammerding J; Vickers TA; Meta M; Coté N; Gavino B; Qiao X; Chang SY; Young SR; Yang SH; Stewart CL; Lee RT; Bennett CF; Bergo MO; Young SG
    J Clin Invest; 2006 Mar; 116(3):743-52. PubMed ID: 16511604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rescue of heterochromatin organization in Hutchinson-Gilford progeria by drug treatment.
    Columbaro M; Capanni C; Mattioli E; Novelli G; Parnaik VK; Squarzoni S; Maraldi NM; Lattanzi G
    Cell Mol Life Sci; 2005 Nov; 62(22):2669-78. PubMed ID: 16261260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of LMNA splicing as a strategy to treat prelamin A diseases.
    Lee JM; Nobumori C; Tu Y; Choi C; Yang SH; Jung HJ; Vickers TA; Rigo F; Bennett CF; Young SG; Fong LG
    J Clin Invest; 2016 Apr; 126(4):1592-602. PubMed ID: 26999604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imbalanced nucleocytoskeletal connections create common polarity defects in progeria and physiological aging.
    Chang W; Wang Y; Luxton GWG; Östlund C; Worman HJ; Gundersen GG
    Proc Natl Acad Sci U S A; 2019 Feb; 116(9):3578-3583. PubMed ID: 30808750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.